Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection

David S Fedson, Steven M Opal, Ole Martin Rordam, David S Fedson, Steven M Opal, Ole Martin Rordam

Abstract

Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.

Keywords: COVID-19; endothelial dysfunction; generic drugs; host response treatment.

Copyright © 2020 Fedson et al.

References

    1. Chen Y, Liu Q, Guo D. 2020. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 92:418–423. doi:10.1002/jmv.25681.
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. 7 February 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA doi:10.1001/jama.2020.1585.
    1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly; 2:113–122. . Accessed 18 February 2020.
    1. Fedson DS. 2015. A practical treatment for patients with Ebola virus disease. J Infect Dis 21:661–662. doi:10.1093/infdis/jiu474.
    1. Shyamsundar M, McKeown STW, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF. 2009. Simvastatin decreases lipopoly-saccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179:1107–1114. doi:10.1164/rccm.200810-1584OC.
    1. Chen W, Sharma R, Rizzo AN, Siegler JH, Garcia JG, Jacobson JR. 2014. Role of claudin-5 in the attenuation of murine acute lung injury by simvastatin. Am J Respir Cell Mol Biol 50:328–336. doi:10.1165/rcmb.2013-0058OC.
    1. Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, Qi J, Xiao Z. 2009. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 3:500–506. doi:10.1097/SHK.0b013e318189017a.
    1. Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, Zhou M, Jiang W. 2015. Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep 5:8209. doi:10.1038/srep08209.
    1. Fedson DS. 2016. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med 4:421. doi:10.21037/atm.2016.11.03.
    1. Fedson DS, Jacobson JR, Rordam OM, Opal SM. 2015. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. mBio 6:e00716-15. doi:10.1128/mBio.00716-15.
    1. Fedson DS, Rordam OM. 2015. Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 36:80–84. doi:10.1016/j.ijid.2015.04.019.
    1. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, PALM Writing Group, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J, PALM Consortium Study Team. 2019. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381:2293–2303. doi:10.1056/NEJMoa1910993.
    1. Fedson DS. 2019. Treating Ebola in eastern DRC. Lancet Infect Dis 19:1059–1060. doi:10.1016/S1473-3099(19)30484-0.
    1. Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, van Goor H, Kamilic J, Florquin S, Bos AP. 2011. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. J Pathol 225:618–627. doi:10.1002/path.2987.
    1. Tikoo K, Patel G, Kumar S, Karpe PA, Sanghavi M, Malek V, Srinivasan K. 2015. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol 93:343–351. doi:10.1016/j.bcp.2014.11.013.
    1. Wösten-van Asperen RM, Bos AP, Bem RA, Dierdorp BS, Dekker T, van Goor H, Kamilic J, van der Loos CM, van den Berg E, Bruijn M, van Woensel JB, Lutter R. 2013. Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome. Pediatr Crit Care Med 14:e438–e441. doi:10.1097/PCC.0b013e3182a55735.
    1. Steinberg BE, Goldenberg NM, Lee WL. 2012. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antiviral Res 93:2–15. doi:10.1016/j.antiviral.2011.10.019.
    1. Pirofski LA, Casadevall A. 2018. The Damage-Response Framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases. J Infect Dis 218(Suppl 1):S7–S11. doi:10.1093/infdis/jiy083.
    1. Fedson DS. 2018. Clinician-initiated research on treating the host response to pandemic influenza. Hum Vaccin Immunother 14:790–795. doi:10.1080/21645515.2017.1378292.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться